RCS - Oxford BioDynamics - Study confirms clinical utility of EpiSwitch CiRT

Oxford BiodynamicsAnnouncement

04/09/2025 10:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250904:nRSD0332Ya&default-theme=true

RNS Number : 0332Y  Oxford BioDynamics PLC  04 September 2025

Oxford BioDynamics plc

("Oxford BioDynamics" or the "Company")

 

OBD's EpiSwitch CiRT Proven to Impact Clinical Treatment Decisions in
Published Study

·      Results strongly support CiRT's clinical utility in guiding
immunotherapy decisions across a broad range of solid tumors

·      CiRT test influenced real-world treatment choices in 61% of cases

·      Company plans to apply for inclusion in US National Comprehensive
Cancer Network clinical guidelines later this year

 

Oxford, UK - 04 September 2025 - Oxford BioDynamics Plc (AIM: OBD), a
precision clinical diagnostics company bringing specific and sensitive tests
to the practice of medicine based on its EpiSwitch® 3D genomics platform,
announces the publication of interim results from its milestone FDA-registered
PROWES trial (NCT06635954 (https://clinicaltrials.gov/study/NCT06635954) ).
The study, published in the high-impact medical journal Cancers(1),
demonstrates the clinical utility and treatment impact of its EpiSwitch CiRT
(https://mycirt.com/index.html) (Checkpoint inhibitor Response Test).

 

The peer-reviewed publication of the ongoing PROWES prospective real-world
study evaluated the clinical utility of OBD's CiRT blood test in guiding
treatment decisions for 205 patients receiving immune checkpoint inhibitors
(ICIs) across a broad range of advanced solid tumours. CiRT is a clinically
validated blood test that predicts a cancer patient's likely response to ICIs,
with high sensitivity (93%), specificity (82%) and accuracy (85%), across the
most widely used ICIs(2-3).

 

Thomas Guiel, COO of Oxford BioDynamics, said: "The PROWES results represent a
significant milestone that further validates the transformative real-world
impact of the EpiSwitch CiRT test on decision-making in real clinical
practice.

 

 "These results not only strengthen the scientific foundation of CiRT, but
also support our strategy to secure inclusion in NCCN (National Comprehensive
Cancer Network) clinical guidelines. The Company expects to apply for
inclusion later this year, which is a critical step towards driving widespread
adoption and achieving our commercial objectives."

 

The findings show that CiRT influenced oncologists' treatment choices in 61%
of cases-including key decisions to initiate, escalate, de-escalate, or avoid
therapy. Among patients with a Low Probability of Response CiRT result, nearly
half avoided ineffective treatment, reducing unnecessary exposure to
potentially serious or life-threatening toxicity. Conversely, almost
three-quarters with a High Probability of Response had their treatment
continued or escalated.

 

The study further demonstrated that CiRT results closely matched real-world
patient outcomes and had broad applicability, remaining consistent across
race, ethnicity, socioeconomic status, and whether treatment was in a major
medical centre or community practice. Unlike existing invasive tissue-based
tests, such as PD-L1 expression or genetic testing (TMB, MMR/MSI), often
limited by poor predictive power, tumour type, and require biopsy or surgical
access, CiRT provides a universally applicable, minimally invasive,
easy-to-interpret result based on a patient's personal immune system
readiness. Patients having a Low Probability of Response were significantly
more likely to experience disease progression, whereas those with High
Probability were more likely to respond with longer-lasting disease control.

 

Early data also suggest CiRT may be used as a tool to monitor emerging
resistance to ICIs, as some patients showed shifts from High to Low
Probability of Response that matched their disease progression.

 

These findings underscore CiRT's potential to personalise care pathways,
improve patient outcomes and deliver significant cost efficiencies. Given that
ICIs and supportive care costs can exceed $850,000 per patient, there is a
substantial opportunity for savings by avoiding costs associated with
ineffective treatment and related adverse events. The authors highlight that
stopping an ineffective therapy just one or two cycles earlier saves many
multiples of the cost of the CiRT test.

 

CiRT is available privately in the UK, covered by Bupa, and in the US with a
unique PLA reimbursement code.

The peer-reviewed manuscript, titled "Clinical Utility of the EpiSwitch CiRT
Test to Guide Immunotherapy Across Solid Tumors: Interim Results from the
PROWES Study", is available online: www.mdpi.com/3483654
(https://www.mdpi.com/3483654)

 

 

References:

 1  Abdo, J., Berghausen, J., et al. (2025). Clinical Utility of the EpiSwitch
CiRT Test to Guide Immunotherapy Across Solid Tumors: Interim Results from the
PROWES Study, Cancers. https://www.mdpi.com/3483654
(https://www.mdpi.com/3483654)

 2  Hunter, E., Salter, M., et al. (2023). Development and Validation of
Blood-Based Predictive Biomarkers for Response to PD-1/PD-L1 Checkpoint
Inhibitors: Evidence of a Universal Systemic Core of 3D Immunogenetic
Profiling across Multiple Oncological Indications. Cancers.
https://doi.org/10.3390/cancers15102696
(https://doi.org/10.3390/cancers15102696)

 3  Ouf, M., Aggarwal, N., et al. (2025). Evaluation of EpiSwitch in
predicting immunotherapy response in hepatocellular carcinoma and
gastrointestinal tumours. Journal of Clinical Oncology.
https://doi.org/10.1200/JCO.2025.43.4_suppl.623
(https://doi.org/10.1200/JCO.2025.43.4_suppl.623)

-Ends-

For further information please contact:

 Oxford BioDynamics Plc                       +44 (0)1865 518910

 Iain Ross, Executive Chairman

 Paul Stockdale, CFO

 Camarco - Financial PR

 Marc Cohen / Tilly Butcher / Fergus Young    +44 (0)20 3757 4980

                                              OBDFinancial@camarco.co.uk

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
 (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
 (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(http://www.oxfordbiodynamics.com/) ,  X (@OxBioDynamics) or LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUWABUPAURC